Background: The purpose of this study was to assess the efficacy and toxicity of capecitabine and cisplatin (XP) combination chemotherapy in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
Patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) have a poor prognosis. Approximately two-third of patients present with locally or regionally advanced disease, and 65% of these patients will relapse after primary therapy and require additional chemotherapy. Therefore, most of the patients with SCCHN will become candidates for palliative chemotherapy. However, the efficacy of palliative chemotherapy has not been satisfactory. When treated with chemotherapy alone, the patients with metastatic or recurrent SCCHN have a median survival of 6-10 months and a 1-year survival rate of up to 40%. The most commonly used drugs include methotrexate, cisplatin, carboplatin, 5-fluorouracil (5-FU), paclitaxel (Taxol), docetaxel (Taxotere), or cetuximab as a single agent, with reported response rates ranging from 15% to 42% [1] . For the combination regimens, cisplatin and 5-FU (PF) is a widely accepted regimen used in patients with metastatic or recurrent disease; it has been shown to be superior to other combinations in response rate without a significant improvement of overall survival (OS) [2] [3] [4] . Recently, the EXTREME study, which compared the classic PF with the same regimen plus cetuximab, has shown remarkable results [5] .
Capecitabine is an oral fluoropyrimidine carbamate designed to replace continuous 5-FU infusion and to generate 5-FU preferentially in tumor tissues. The oral administration of capecitabine enables chronic daily dosing and allows for the effects of continuous 5-FU infusion without the serious complications and inconvenience associated with central venous catheter access. In addition, capecitabine offers the potential for a more convenient outpatient treatment. As a single agent, capecitabine has demonstrated activity in metastatic breast cancer, colorectal cancer and nasopharyngeal carcinoma [6] [7] [8] . Recently, encouraging results have been reported with capecitabine and cisplatin (XP) combination in patients with recurrent gastric cancer, metastatic esophageal cancer, and advanced biliary cancer [9] [10] [11] . The present phase II study was performed to assess the safety and efficacy of the XP regimen in patients with metastatic or recurrent SCCHN.
In addition, thymidylate synthase (TS), thymidine phosphorylase (TP), and excision repair crosscomplementation group 1 (ERCC1) expression was evaluated by immunohistochemistry (IHC) to determine their association with clinical outcomes after treatment with XP. Low TS expression has been reported to be associated with the high antitumor efficacy of oral fluoropyrimidine or 5-FU in SCCHN and gastric and colorectal cancers [12] [13] [14] . Furthermore, higher levels of TP expression have been associated with increased intratumoral microvessel density and an unfavorable prognosis [15] . ERCC1 has been shown to play a key role in nucleotide excision repair and in removing platinum-induced DNA adducts. ERCC1 has been associated with resistance to platinum-based chemotherapy [16] .
patients and methods

patient eligibility
Eligible patients were required to have histologically or cytologically confirmed SCCHN: recurrent disease or previously untreated metastatic disease. Other eligibility criteria included the following: at least one measurable lesion according to the RECIST, age 18 years or more, an Eastern Cooperative Oncology Group performance status of £2, a life expectancy of at least 3 months, adequate bone marrow function [hemoglobin ‡10.0 g/dl, absolute neutrophil count (ANC) ‡1500/ll, and platelet count ‡100 000/ll], and adequate renal function (creatinine <1.5 mg/dl) and liver function [aspartate aminotransferase, alanine aminotransferase three times or less than the upper limits of normal (ULN) range, and total bilirubin less than two times the ULN]. Patients were excluded from the study if they had previous palliative chemotherapy. However, neoadjuvant chemotherapy or concurrent chemoradiotherapy (CCRT) before 6 months from the study enrollment was allowed. The other exclusion criteria included history of another malignancy; presence of pregnancy or lactation; presence or history of brain metastasis; history of clinically significant cardiac disease as defined by a serious arrhythmia, congestive heart failure, myocardial infarction, or unstable angina within 6 months; and active serious infection or psychiatric illness that would preclude obtaining informed consent. Patients with nasopharyngeal carcinoma were excluded from the study.
All patients provided written informed consent before enrollment in the study, which was approved by the Institutional Review Board.
treatment schedule
The chemotherapy regimen consisted of capecitabine 1250 mg/m 2 orally twice a day on day 1 to day 14 and cisplatin 60 mg/m 2 i.v. on day 1. Each cycle was repeated every 3 weeks. Patients were continued on treatment until documented disease progression, unacceptable toxicity, the patient declined further treatment, or for a maximum of six cycles. For emesis prophylaxis, 5-hydroxytryptamine-3 antagonists and dexamethasone were provided before chemotherapy.
dose modifications
The acceptable duration of treatment delay due to adverse events was a maximum of 3 weeks. If patients required a delay of longer than 3 weeks for recovery, they went off of the study protocol. Acceptable maximum level of dose reduction for both hematologic and nonhematologic toxic effects was 50%. When doses were reduced for toxicity, reescalation of the dose was not permitted.
capecitabine dose modification. If ANC was >1000/ll and platelet count was >75 000/ll, chemotherapy was administered without dose reductions after recovery. If ANC was <1000/ll or platelet count was <75 000/ll, capecitabine dose was reduced by 25%. If grade 3 or 4 capecitabine-related nonhematologic toxicity occurred, capecitabine was withheld until the toxicity improved by at least two grade levels and capecitabine dose was reduced by 25%. For grade 1 or 2 nonhematologic toxic effects, dose reduction or delay of treatment schedule was not allowed.
cisplatin dose modification. For hematologic toxic effects, dose reduction was not performed and chemotherapy was held until ANC was ‡1000/ll and platelet count was ‡75 000/ll. If grade 3 or 4 cisplatin-related nonhematologic toxic effects were developed, cisplatin dose was reduced by 25%. For grade 1 or 2 nonhematologic toxic effects, dose reduction or delay of treatment schedule was not allowed.
efficacy and safety
Pretreatment evaluation included history and physical examination, complete blood cell (CBC) count with differentials, blood chemistry, chest X-ray, computed tomography (CT) scanning or magnetic resonance imaging of the head and neck, and other imaging studies as clinically indicated. During treatment, history and physical examination including toxicity assessment, CBC with differential and blood chemistry was performed every 3 weeks before each cycle. Appropriate imaging studies including CT scans of the head and neck were performed every two cycles (6 weeks) to evaluate the treatment response or sooner if needed for documentation of disease progression. Responses were evaluated in patients who had received at least two cycles. The objective response was assessed according to RECIST criteria [17] . Patients who received at least one cycle of treatment were assessed for toxicity. The progression-free survival (PFS) was calculated from the first day of treatment to the date of the first documentation of disease progression or the last follow-up. OS was calculated from the first day of treatment to the date of death or the last follow-up. Toxicity was assessed according to NCI-CTC version 3.0.
statistical analysis
The minimax two-stage design described by Simon for a phase II clinical trial was used to calculate sample size and minimize the number of patients required. This trial was designed to detect a response rate [partial response (PR) and complete response (CR)] of 40% compared with a minimal clinically meaningful response rate of 20%. Sample size was determined based on the following assumptions: alpha error 0.05 and beta error 0.2. According to the two-stage design, when 18 patients who fit the study criteria were entered, if four or fewer responses were observed, accrual would stop because of the conclusion that the regimen did not hold promise for further study. Otherwise, accrual continued to a total of 33 patients. The treatment was considered effective if ‡10 responses were observed in 33 patients. The response rate and patient clinical characteristics were evaluated using the chi-square test or Fisher's exact test for categorical variables. The OS and PFS were calculated by the Kaplan-Meier method and the 95% confidence interval (CI) for the median time to an event.
immunohistochemical stains
Immunohistochemical studies for ERCC1, TS, and TP were carried out on formalin-fixed, paraffin-embedded 4-lm-thick tissue sections. The primary antibodies used were mouse monoclonal antibody for ERCC1 (clone 8F1, 1 : 300; GeneTex, San Antonio, TX), TS (clone TS106, 1 : 50; Zymed, Carpinteria, CA), and TP (Clone: P-GF.44C, 1 : 100; Thermo Scientific Lab original article
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Vision, Fremont, CA). Tissue sections were deparaffinized three times in xylene for a total of 15 min and subsequently rehydrated. Antigen retrieval was carried out in a 750-W microwave oven for 5 min three times in Tris-EDTA buffer (pH 9.0) for ERCC1 and in citrate buffer (pH 6.0) for TS. No antigen retrieval was performed for TP. After blocking the endogenous peroxidase activity with 3% hydrogen peroxidase for 10 min, the primary antibody incubation for ERCC1 was carried out for 90 min at room temperature, and the primary antibody incubation for TS and TP was carried out for 30 min at room temperature. The antigen-antibody reaction was detected using the DAKO ChemMateä DAKO Envisionä Detection Kit, Peroxidase/DAB K5007 (DAKO, Glostrup, Denmark). Counterstaining was performed with Mayer's hematoxylin. Staining for ERCC1 was considered to be positive when tumor cells were observed to have nuclei. The staining for TS and TP was considered to be positive when the tumor cells were observed to have nuclei or cytoplasm reactivity. Negative controls (isotype-matched irrelevant antibody) were run simultaneously. The slides were assessed without knowledge of the clinical outcome by two pathologists (Dr IGD and YHK). The intensity and extent of IHC staining were graded as the following. The intensity was graded on a semiquantitative scale from 0 to +3, where 0 = no staining, +1 = weak staining, +2 = strong staining, and +3 = very strong staining. The area of the most intense staining was graded on a scale from 0 to 4, where 0 = no staining, +1 = staining of 0%-10% of tumor cells, +2 = staining of 10%-25% of tumor cells, +3 = staining of 25%-50% of tumor cells, and +4 = staining of >50% of the tumor cells. A H-score was calculated by multiplying the intensity and extent grades as described previously. The median H-score was chosen as the cut-off point for separating positive tumors from negative tumors, as described previously [18, 19] .
results According to the previously described minimax two-stage design, 18 patients who fit the criteria were enrolled at 28 months after initiation of the study and 7 patients (38.9%) achieved a PR. Therefore, the study proceeded to the next stage and a total of 36 patients were enrolled into the study between May 2004 and December 2008.
patient characteristics
Patient baseline characteristics are listed in Table 1 . The median age was 62 years, and the range was from 33 to 81 years of age. The most common site of metastasis was the lungs (38.9%), followed by the lymph nodes (30.6%), bones (11.1%), brain (2.8%), and pleura (2.8%). The most common primary site was the oral cavity followed by the larynx, oropharynx, and hypopharynx. Most of the patients (72.2%) had recurrent disease at the time of enrollment. Before disease relapse, the patients with recurrent disease were treated by various therapies such as surgery, CCRT, or radiotherapy alone according to disease status at that time. The past treatment modalities of the patients with recurrent disease were operation (22/26, 84.6%), CCRT (3/26, 11.5%), and radiotherapy (1/26, 3.8%).
treatment administration
A total of 137 cycles were administrated, with a median of 4 cycles per patient. The capecitabine dose was reduced in 45 cycles (32.8%) out of all cycles. Fourteen patients (38.9%) required capecitabine dose reductions because of neutropenia (7/36, 19.4%), hand-foot syndrome (2/36, 5.6%), diarrhea (2/36, 5.6%), thrombocytopenia (1/36, 2.8%), anorexia (1/36, 2.8%), and mucositis (1/36, 2.8%). The mean relative dose intensity was 92.9% of the planned dose of capecitabine.
response and survival
Among the 36 patients, 33 patients could be evaluated for tumor response. Three patients were excluded from the evaluation. One patient withdrew consent before treatment and another patient was not assessable because of loss to follow-up. Another patient refused further chemotherapy after the first cycle. Among the 33 patients who could be evaluated, 18 (50.0%) achieved a PR and 5 (13.9%) had stable disease. There was no patient with a CR. On the intent-to-treat analysis, the overall response rate (ORR) was 50.0% (CR, 0/36; PR, 18/36; 95% CI 32% to 67%) ( Table 2 ). There was no significant difference in the ORR between patients with metastatic disease and recurrent disease. The median PFS was 3.7 months (95% CI 2.1-5.3 months), with a median response duration in responders of 4.9 months (range, 1.6-18.6 months). The median follow-up duration was 10.8 months (range, 1.1-41.3 months). The median OS and 1-year survival rate were 10.3 months (95% CI 8.5-12.1 months) and 43.3%, respectively (Figures 1 and 2) . Table 3) . There was no treatment-related death.
association of TS, TP, and ERCC1 expression with treatment outcomes
A total of 27 patients had tumor samples available for IHC studies of TP, TS, and ERCC1 protein expression. In addition, 7 patients (43.8%) who were ERCC1 negative (16 patients) had a PR, whereas 6 (54.5%) of 11 had a PR in ERCC1-positive patients. Neither the TP score nor the TS score was significantly associated with response (TP score £ 8 versus TP score > 8, P-value = 1.00; TS score £ 6 versus TS score > 6, P-value = 0.63). In addition, there was no significant difference in response rates between ERCC1-positive and -negative tumors (P-value = 0.47) (Table 4) . Furthermore, there were no significant differences in the OS according to the TP, TS, and ERCC1 expression (TP negative, 9.6 months versus TP positive, 9.5 months, P-value = 0.28; TS negative, 9.5 months versus TSpositive, 9.7 months, P-value = 0.25; ERCC1-negative, 9.5 months versus ERCC1-positive, 9.8 months, P-value = 0.66).
discussion
The results of this study suggest that the combination of capecitabine and cisplatin has antitumor activity and acceptable safety profile in patients with metastatic or recurrent SCCHN. This combination regimen demonstrated an ORR of 50%, median PFS of 3.7 months, and median OS of 10.3 months. These results suggest equivalent efficacy of XP regimen compared with cisplatin and infusion of 5-FU combination, which is a widely accepted regimen for the treatment of original article Annals of Oncology metastatic or recurrent disease [1] . The results of this trial are supported by the findings of other study. A phase II study in 41 patients with recurrent or unresectable SCCHN showed that the XP combination was an effective regimen. The study patients received cisplatin 75 mg/m 2 on day 1 and capecitabine 2000 mg/m 2 on day 1 to day 14, every 3 weeks. Sixteen CRs (39%) and 12 PRs (29%) were documented, for an ORR of 68%. The median PFS and OS was 6.4 and 12.6 months, respectively [20] .
In a recent randomized clinical trial, compared with PF alone, a cetuximab plus PF regimen improved OS as the firstline treatment in patients with recurrent or metastatic SCCHN. The median OS was 7.4 months in the PF-alone group and 10.1 months in the group that received PF plus cetuximab (hazard ratio for death, 0.80; P-value = 0.04). The addition of cetuximab prolonged the median PFS from 3.3 to 5.6 months (hazard ratio for progression, 0.54; P < 0.001) and increased the response rate from 20% to 36% (P < 0.001). The toxic effects were tolerable without cetuximab-related deaths [5] . Although the present study was a nonrandomized design and the number of the enrolled patients was small, the OS, PFS, and response rate of the XP regimen were comparable with PF plus cetuximab. However, continuous infusion via permanent i.v. access devices of PF plus cetuximab can cause a variety of complications, such as catheter-related infections, thrombosis, or pneumothorax [21] . Thus, the oral capecitabine and cisplatin regimen could be an alternative option for the treatment of advanced SCCHN. Additionally, further studies for cetuximab plus XP regimen may be worth.
However, the improvement in response rates associated with the use of XP combination chemotherapy did not translate into the prolongation of OS. Therefore, toxic effects and quality of life would be more important considerations with regard to this treatment. In the present study, adverse events were generally mild and manageable without treatment-related death. The common adverse events that require capecitabine dose reduction and can interfere with daily activities were neutropenia, hand-foot syndrome, and diarrhea. All grades of the hand-foot syndrome were observed in 32.8% of cycles, with a frequency similar to previous reports [9] [10] [11] 20] . However, these events were manageable by treatment interruption or dose modification. The oral administration of tablets or capsules may be difficult in patients with SCCHN who have dysphagia or odynophagia. However, in the present study, there was no difficulty or failure in the attempts at swallowing capecitabine tablets, and the mucositis that developed after the XP regimen administration was tolerable. Although a pivotal phase I study reported the recommended doses for XP, for further phase II studies they were cisplatin 100 mg/m 2 on day 1 and capecitabine 1000 mg/m 2 twice a day on day 1 to day 14 every 3 weeks [22] ; however, there was no evidence of a doseresponse relationship (high dose, 120 mg/m 2 versus low dose, 60 mg/m 2 ) of cisplatin activity in patients with advanced SCCHN in a previous randomized trial [23] . In the present study, grade 3 or 4 mucositis was noted in only 3.6% of patients. Therefore, the cisplatin dose (60 mg/m 2 ) used in this study appears to be optimal without losing efficacy.
Our study has several limitations. First, the study has the possibility of selection biases associated with a single institution study. As a potential bias, only 11.1% of patients in this study had received prior radiotherapy (including CCRT and radiation alone). This figure is quite low compared with other reported studies of metastatic or recurrent SCCHN patients. In the EXTREME trial, for example, 85% of patients had received prior radiotherapy. It is possible, in fact highly likely, that the high OS, 1-year survival, and response rates of the present study are attributable to selection of a more favorable less heavily treated patients population. In addition, the higher proportion of the patients who did not receive radiotherapy may affect the toxicity profile of the XP regimen. Usually, the patients receiving head and neck radiotherapy, particularly those treated Figure 3 . Immunohistochemistry of thymidine phosphorylase (TP), thymidylate synthase (TS), and excision repair cross-complementation group 1 (ERCC1). Representative cases of +3 positive staining for TP (A), TS (B), and ERCC1 (C); magnification ·200.
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with CCRT, experience more severe adverse events that may be exacerbated by subsequent systemic chemotherapy. To identify predictive markers for the treatment response to XP in this cohort, tumor specimens were collected from 27 patients and stained for TP, TS, and ERCC1. There was no predictive value identified for TP, TS, or ERCC1 associated with the treatment outcome in this study. However, we reported that a low expression of ERCC1 in patients with locally advanced SCCHN was correlated with a higher rate of CR to CCRT compared with high expression of ERCC1, although the overall response did not significantly differ [24] . Another study reported that a low TP expression in pretreatment biopsies was associated with a high rate of CR after CCRT [25] . The discrepant results for these markers might be attributable to the small number of specimens in this study. Another possibility might be the inherent limitations of IHC stains. The evaluation of grade and extent of expression of biomarkers tends to be subjective even though two pathologists inspected the samples independently. Moreover, there are no reproducible and standardized criteria defining a positive stain for each biomarker.
In conclusion, the combination of capecitabine and cisplatin has antitumor activity and acceptable safety profile in patients with metastatic or recurrent SCCHN; there were no serious complications and the risks associated with a central venous catheter access were avoided. The regimen appears to be equivalent to PF regimen in outcome and toxicity. The use of one regimen over the other may depend on the availability of home infusion, access to expensive oral drugs, and patient compliance. Based on the results of the present study, this treatment regimen warrants further investigation. However, the focus of this investigation should be to examine a more representative patient population.
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